---
title: Identifying disease-modifying potential in myelofibrosis clinical trials
date: '2024-08-22'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39172741/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240823182241&v=2.18.0.post9+e462414
source: Blood
description: The ultimate goal of bringing most new drugs to the clinic in hematological
  malignancy is to improve overall survival. However, the use of surrogate endpoints
  for overall survival is increasingly considered standard practice, since a well
  validated surrogate endpoint can accelerate the outcome assessment and facilitate
  better clinical trial design. Established examples include monitoring minimal residual
  disease in chronic myeloid leukemia and acute leukemia, and metabolic response assessment
  ...
disable_comments: true
---
The ultimate goal of bringing most new drugs to the clinic in hematological malignancy is to improve overall survival. However, the use of surrogate endpoints for overall survival is increasingly considered standard practice, since a well validated surrogate endpoint can accelerate the outcome assessment and facilitate better clinical trial design. Established examples include monitoring minimal residual disease in chronic myeloid leukemia and acute leukemia, and metabolic response assessment ...